Allergan Plc (AGN2)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Brenton L. Saunders
Employees:
MORRIS CORPORATE CENTER III, 400 INTERPACE PARKWAY, PARSIPPANY, NJ, 07054
9092701400

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded on in 1984 and is headquartered in Dublin, Ireland.

Data derived from most recent annual or quarterly report
Market Cap 63.504 Billion Shares Outstanding329.002 Million Avg 30-day Volume 4.992 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-4.56
Price to Revenue0.0 Debt to Equity1.6837 EBITDA746.7 Million
Price to Book Value0.0 Operating Margin-4.3133 Enterprise Value0
Current Ratio1.451 EPS Growth-4.398 Quick Ratio0.62
1 Yr BETA 0.4731 52-week High/Low 0.0 / Profit Margin-7.4995
Operating Cash Flow Growth17.041 Altman Z-Score0.0 Free Cash Flow to Firm -5.215 Billion
View SEC Filings from AGN2 instead.

View recent insider trading info

Allergan Plc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AGN2 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AGN2 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COUGHLIN CHRISTOPHER J

  • Director
 No longer subject to file 2020-05-08 0

BODINE CHRIS W

  • Director
 No longer subject to file 2020-05-08 0

HUGIN ROBERT J

  • Director
 No longer subject to file 2020-05-08 0

FREYMAN THOMAS C

  • Director
 No longer subject to file 2020-05-08 0

SAUNDERS BRENT L CHAIRMAN, PRESIDENT AND CEO

  • Officer
  • Director
 No longer subject to file 2020-05-08 0

WALSH MATTHEW M EVP, CHIEF FINANCIAL OFFICER

  • Officer
 No longer subject to file 2020-05-08 0

DAVIDSON CAROL ANTHONY

  • Director
 No longer subject to file 2020-05-08 0

BROWN ADRIANE M

  • Director
 No longer subject to file 2020-05-08 0

BASGOZ NESLI

  • Director
 No longer subject to file 2020-05-08 0

MEURY WILLIAM EVP & CHIEF COMMERCIAL OFFICER

  • Officer
 No longer subject to file 2020-05-08 0

MCDONNELL PETER J

  • Director
 No longer subject to file 2020-05-08 0

DARECCA JAMES SVP CHIEF ACCOUNTING OFFICER

  • Officer
 No longer subject to file 2020-05-08 0

BAILEY A ROBERT D EVP CHIEF LEGAL OFF & CORP SEC

  • Officer
 No longer subject to file 2020-05-08 0

NICHOLSON C. DAVID EVP CHIEF R&D OFFICER

  • Officer
 No longer subject to file 2020-05-08 0

BOCCUZI JOSEPH H

  • Director
 No longer subject to file 2020-05-08 0

SWANTON WAYNE R EVP, GLOBAL OPERATIONS

  • Officer
 No longer subject to file 2020-05-08 0

GREENBERG MICHAEL ELDON

  • Director
 No longer subject to file 2020-05-08 0

KLEMA CATHY

  • Director
 25,081 2019-04-30 0

LING KAREN EVP & CHIEF H.R. OFFICER

  • Officer
 25,132 2019-04-03 0

WEISS FRED G

  • Director
 29,675 2018-05-02 0

BISARO PAUL

  • Director
 383,729 2018-05-02 0

O'SULLIVAN PATRICK J

  • Director
 6,633 2018-05-02 0

HILADO MARIA TERESA EXECUTIVE VICE PRESIDENT

  • Officer
 25,911 2018-04-03 0

TAYLOR RONALD R

  • Director
 25,305 2017-12-31 0

STEWART ROBERT A CHIEF OPERATING OFFICER

  • Officer
 No longer subject to file 2017-12-29 0

PRINCEN MARC EVP AND PRESIDENT INT'L COMML

  • Officer
 11,790 2017-05-04 0

BLOEM JAMES H

  • Director
 11,163 2017-05-03 0

GALLAGHER MICHAEL R

  • Director
 No longer subject to file 2017-05-03 0

SCHAISON PHILIPPE EVP, PRESIDENT ALLERGAN MED

  • Officer
 No longer subject to file 2016-06-08 0

NAVARRE PAUL EVP, PRESIDENT INT'L BRANDS

  • Officer
 No longer subject to file 2016-06-08 0

TURNER ANDREW L

  • Director
 No longer subject to file 2015-03-17 0

KING JOHN A

  • Director
 No longer subject to file 2015-03-17 0

HOWSON TAMAR D

  • Director
 No longer subject to file 2015-03-17 0

MICHAL JIRI

  • Director
 No longer subject to file 2015-03-17 0

BUCHEN DAVID A SEE REMARKS

  • Officer
 74,050 2015-03-05 0

MAYR CHARLES M CHIEF COMMUNIC OFFICER

  • Officer
 15,037 2015-03-05 0

PAONESSA ALBERT III PRESIDENT ANDA, INC.

  • Officer
 21,856 2014-09-08 0

JOYCE R TODD CHIEF FINANCIAL OFFICER

  • Officer
 0 2014-07-01 0

FRIDRIKSDOTTIR HAFRUN SVP, GLOBAL R&D

  • Officer
 6,914 2014-05-09 0

WILKINSON GEORGE FRED PRES-ACTAVIS SPECIALTY BRANDS

  • Officer
 15,412 2013-11-27 0

OLAFSSON SIGURDUR O PRES.-ACTAVIS PHARMA

  • Officer
  • Director
 71,947 2013-11-11 0

EBERT CHARLES D SVP, BRANDS R&D

  • Officer
 7,611 2013-11-06 0

EAGAN PATRICK CHIEF HR OFFICER-GLOBAL

  • Officer
 7,009 2013-11-04 0

FEDIDA MICHAEL J

  • Director
 No longer subject to file 2013-10-01 0

FELDMAN MICHEL J

  • Director
 No longer subject to file 2013-10-01 0

HUMMEL ALBERT F

  • Director
 No longer subject to file 2013-10-01 0

MICHELSON JACK

  • Director
 No longer subject to file 2013-10-01 0

MENARD FRANCOIS A SVP,GLOBAL GENERICS R&D

  • Officer
 37,016 2012-05-29 0

TABATZNIK ANTHONY SELWYN

  • Director
 6,064 2012-05-11 0

CARMICHAEL CLARE SR VP, HUMAN RESOURCES

  • Officer
 16,447 2011-03-05 0

RUSSILLO THOMAS R EVP, GLOBAL GENERICS

  • Officer
 57,868 2010-12-31 0

MUNRO GORDON SR. VP, QUALITY ASSURANCE

  • Officer
 18,861 2010-03-16 0

BOYER ANDREW S SVP,SALES&MKTG,US GENERICS

  • Officer
 38,913 2010-03-14 0

MIRANDA DIANE F VP,GENERIC MARKETING & OPER.

  • Officer
 19,089 2010-03-14 0

AMATO LYNNE VP, BRAND SALES & OPERATIONS

  • Officer
 18,443 2010-03-14 0

GIORDANO THOMAS R SR VP AND CIO

  • Officer
 31,052 2010-03-14 0

HEIMERS EDWARD F JR EVP AND PRESIDENT, BRAND DIV.

  • Officer
 21,826 2010-03-14 0

POWER ANNA SR VP,GLOBAL GENERICS

  • Officer
 6,800 2010-02-24 0

EISENHAUR PATRICIA L. VP, INVESTOR RELATIONS

  • Officer
 7,865 2009-08-12 0

BRUNNER PATRICK G. SVP,MANUFACTURING OPERATIONS

  • Officer
 21,033 2009-07-18 0

DURAND MARK SRVP & CFO

  • Officer
 33,966 2009-03-05 0

SKARA SUSAN K SR. VP, HUMAN RESOURCES

  • Officer
 No longer subject to file 2008-09-01 0

HSIA DAVID C SR. VP, SCIENTIFIC AFFAIRS

  • Officer
 1,725,515 2008-09-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MCDONNELL PETER J - Director

2020-05-04 20:55:36 -0400 2022-05-01 F 991 $189.74 d 6,352 direct 0.5758 0.5758 2 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments